No cause for panic, but an incentive to improve clinical practice
The use of selective serotonin reuptake inhibitors (SSRIs) in depressed children and adolescents has received consider-able attention in the past year; this attention has included concerns about increased suicide risk, revised evidence about effectiveness, growing prescription numbers, and revelations of drug companies withholding data.1 The discovery of unforeseen risks in other drugs such as cyclooxygenase-2 inhibitors has intensified the climate of uncertainty and mistrust about drug treatment. Some argue that to diagnose major depression in children is to medicalise the unhappiness caused by affluence, permissiveness, a decaying family and society.2 By contrast, medical practitioners and governments have been told during the last quarter century that depression is a serious illness that can lead to suicide, poor physical health, and personal, professional and social difficulties. Thus, the Australian community has invested considerable resources in trying to tackle this scourge (eg, The National Depression Initiative3). If experts disagree, it is little wonder that the public and clinicians are confused, yet severely depressed teenagers continue to come to doctors for management.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Professor Rey was a member of the advisory committee for Strattera (Eli Lilly) and Concerta (Janssen-Cilag) and was funded by Eli Lilly to attend an international conference. No agency or other source has funded or influenced the design or content of this article. Dr Dudley has often attended dinners sponsored by Pfizer, and received gifts from various drug companies (bags, CDs, pens etc). This has not influenced the content of this article.